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Abstract
Background: Genetic polymorphism of human 8-oxoguanine glycosylase 1 (hOGG1) Ser326Cys (rs1052133) has
been implicated to alter the risk of prostate cancer, but the results are controversial.
Methods: Two investigators independently searched the Medline, and Cochrane Library up to June 7, 2011.
Summary odds ratios (OR) and 95% confidence interval (CI) for Ser326Cys polymorphism and prostate cancer were
calculated. Statistical analysis was performed with the software program Review Manage, version 5.0 and Stata 10.0.
Results: A total of 8 independent studies, including 2584 cases and 3234 controls, were identified. Our analysis
suggested that Ser326Cys was not associated with prostate cancer risk in overall population. In the subgroup
analysis, we detected the significant association between Ser326Cys polymorphism and decreased prostate risk in
mixed population under additive model (OR = 0.67, 95% CI = 0.50-0.90, P = 0.007), recessive model (OR = 0.68,
95% CI = 0.51-0.91, P = 0.008), and Cys allele versus Ser allele (OR = 0.88, 95% CI = 0.78-0.98, P = 0.02). Subanalysis
on Caucasian subjects demonstrated that Ser326Cys was not associated with prostate cancer risk.
Conclusion: This meta-analysis showed the evidence that hOGG1 Ser326Cys polymorphism was associated with a
decreased risk of prostate cancer development in mixed populations.
Background
Prostate cancer (PCa) is one of the most common
malignant diseases among men. The mechanism of its
carcinogenesis, like other cancers, still remains unclear.
Multiple environmental and lifestyle factors may
increase the risk of PCa, including tobacco use, and a
diet poor in fresh fruits and vegetables. However, not all
of those who have been exposed to the risk factors will
develop PCa, suggesting the inter-individual differences
in susceptibility. DNA repair pathways play a critical
role in maintaining the genomic integrity in general and
specialized functions of cells as well as in the prevention
of carcinogenesis, and therefore variations in these
genes may lead to higher susceptibility to PCa.
8-Oxodeoxyguanosine, the most abundant lesion gen-
erated by oxidative stress from the environment and
normal cellular metabolism, is highly mutagenic
resulting in GC to TA transversion [1,2]. hOGG1 gene
located on chromosome 3 encodes a DNA glycosylase/
apurinic-apyrimidinic lyase that catalyzes the excision
and removal of 8-hydroy-2-deoxyguanine adducts [3].
In the past years, the hOGG1 Ser326Cys polymorph-
ism has attracted widespread attention. hOGG1 is abun-
dantly expressed in prostate tissue, the functional
consequences of the hOGG1 Ser326Cys polymorphism
are strongly debated [4]. One study showed that the
hOGG1 326Ser enzyme have higher activity than the
326Cys variant enzyme [5]. Another study data sug-
gested that both 326Ser and 326Cys variant enzymes are
functional and do not exhibit significant differences in
repair activities [6]. The other study indicated that capa-
city to repair oxidative DNA damage was significantly
decreased in individuals with 326Cys/Cys compared
with Ser/Ser and Ser/Cys genotypes [7]. Several eligible
case-control studies were performed to identify the asso-
ciation of Ser326Cys polymorphism with PCa risk
[8-15]. However, the results remain inconclusive and
inconsistent.
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investigate the association of Ser326Cys polymorphism
of hOGG1 gene and PCa. Hence, a meta-analysis based
on a total of 8 independent studies was performed,
which may provide the evidence for association of
hOGG1 Ser326Cys polymorphism with PCa
susceptibility.
Methods
Publication search
We searched the articles using the terms “hOGG1” or
“OGG1”, “polymorphism” or “variation”, “prostate” and
“cancer” in Medline and Cochrane Library, and all eligi-
ble studies were detected before June 7, 2011. We evalu-
ated all associated publications to retrieve the most
eligible literatures. Their reference lists were hand-
searched to find other relevant publications. Of the stu-
dies with overlapping data published by the same inves-
tigators, only the most recent or complete study was
included in this meta-analysis.
Inclusion and exclusion criteria
T h ef o l l o w i n gi n c l u s i o nc r i t e r i aw e r eu s e dt os e l e c tl i t -
eratures for the meta-analysis: (1) Only the case-control
studies were considered; (2) The paper should clearly
describe PCa diagnoses and the sources of cases and
controls; (3) The authors must offer the size of the sam-
ple, OR and their 95% CI or the information that can
help infer the results in the papers. The exclusion cri-
teria were: (1) none-case-control studies; (2) control
population including malignant tumor patients; and (3)
duplicated publications.
Data Extraction
Two investigators reviewed and extracted information
from all eligible publications independently, according
to the inclusion and exclusion criteria listed above. An
agreement was reached by discussion between the two
reviewers whenever there was a conflict. The following
items were collected from each study: first author’s sur-
name, year of publication, statistical data, ethnicity, total
number of cases and controls as well as numbers of
cases and controls with Ser/Ser, Ser/Cys, and Cys/Cys
genotypes, respectively. Different descents were categor-
ized as Caucasian, Asian, African and Mixed, which
included more than one ethnic descent.
Statistical analysis
The effect measure of choice was OR with its corre-
sponding 95% CI. The significance of the summary OR
was determined with a Z-test and P < 0.05 was consid-
ered as statistically significant. In our study, two models
of meta-analysis were applied for dichotomous out-
comes: the fixed-effects model and the random-effects
model. The fixed-effects model assumes that studies are
sampled from populations with the same effect size,
making an adjustment to the study weights according to
the in-study variance. The random-effects model
assumes that studies are taken from populations with
varying effect sizes, calculating the study weights both
from in-study and between-study variances, considering
the extent of variation, or heterogeneity. Heterogeneity
assumption was checked by Q-test. P ≥ 0.10 for the Q-
test indicated lack of heterogeneity among the studies.
Either a random-effects model or fixed-effects model
was used to calculate pooled effect estimates in the pre-
sence or absence of heterogeneity [16,17], respectively.
To explore the effect of heterogeneity among the studies
on the conclusions of this meta-analysis, subgroup ana-
lyses were performed by ethnicity.
Firstly, we examined Ser326Cys genotypes using addi-
tive (Cys/Cys vs Ser/Ser), recessive (Cys/Cys vs Ser/Cys
+ Ser/Ser) and dominant (Cys/Cys + Ser/Cys vs Ser/Ser)
genetic models. Then, the comparison of Cys allele with
Ser allele (allelic model) was examined. An asymmetric
plot indicates a possible publication bias. The symmetry
of the funnel plot was further evaluated by Egger’s linear
regression test. The significance of the intercept was
determined by the t-test suggested by Egger (P < 0.05
was considered representative of statistically significant
publication bias). All statistical tests were performed
with Review Manage, version 5.0 and Stata 10.0 using
two-sided P-values.
Results
Eligible Studies
8 publications on hOGG1 Ser326Cys genotypes and PCa
were identified through literature search and selection
based on the inclusion and exclusion criteria [8-15]. 8
independent studies consisted of 3 Caucasian, 1 Asian, 1
African and 3 mixed populations. In total, 2584 PCa
cases and 3234 controls were included in the meta-ana-
lysis. The selected study characteristics were summar-
ized in Table 1.
Meta-analyses and Evaluation of Heterogeneity and
Publication bias
The meta-analysis for association of Ser326Cys poly-
morphism with PCa in overall population included 8
independent studies with a total of 2584 cases and 3234
controls. The Q-test of heterogeneity was significant
and we conducted analyses using random effect models.
There was no statistically significant difference in Pca
risk between the patients with Cys/Cys genotype and
those with Ser/Ser genotype (OR 1.06, 95% CI = 0.61-
1.87, P = 0.83). Similarly, no significant associations
were found in the recessive model comparison (OR
1.00, 95% CI = 0.61-1.63, P = 0.99) and dominant model
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addition, we did not detect the association between
Ser326Cys polymorphism and PCa when examining the
contrast of Cys versus Ser (OR 1.10, 95% CI = 0.88-1.37;
P = 0.41). In the stratified analysis by ethnicity, signifi-
cant between-study heterogeneity was detected in all the
comparisons in Caucasians, but not in mixed popula-
tion. For mixed population, there was significant asso-
ciation between Ser326Cys polymorphism and decreased
PCa for additive model comparison (OR = 0.67, 95% CI
= 0.50-0.90, P = 0.007; Figure 1), recessive model com-
parison (OR = 0.68, 95% CI = 0.51-0.91, P = 0.008;
Figure 2), and Cys allele versus Ser allele comparison
(OR = 0.88, 95% CI = 0.78-0.98, P = 0.02; Figure 3),
except for the dominant model comparison (OR = 0.90,
95% CI = 0.78-1.03, P = 0.13, data not shown in Figure).
We did not find any associations between Ser326Cys
polymorphism and PCa risk in Caucasians. Begg’s funnel
plot and Egger’s test were performed to assess the publi-
cation bias. The results did not show any evidence of
publication bias in all the comparisons. The detailed
data were shown in Table 2.
Discussion
Several DNA repair pathways are involved in the main-
tenance of genetic stability. The hOGG1 gene is
involved in base excision repair (BER) of DNA repair
pathways. DNA damage generated by different carcino-
genic agents or inflammatory process is repaired mostly
by BER. Common polymorphisms in DNA repair genes
may alter protein function and an individual’s capacity
to repair damaged DNA. Deficits in repair capacity may
lead to genetic instability and carcinogenesis [18,19]. So
allelic variants in the key gene involved in DNA repair
process, hOGG1, may confer an increased risk for PCa
development.
Since the identification of hOGG1 Ser326Cys poly-
morphism, a number of studies have investigated the
genetic effect of this polymorphism on PCa susceptibil-
ity, but the results are inconclusive. As a powerful statis-
tical method, meta-analysis can provide a quantitative
approach for pooling the results of different researches
on the same topic, and for estimating and explaining
their diversity [20,21]. This led us to undertake the
present meta-analysis, which could quantitify all the
available data and might help us to distinguish the true
from the false, to explore a robust estimate of the effect
of this polymorphism on PCa. To the best of our
knowledge, it is the first systematic review that has
investigated the association of hOGG1 Ser326Cys
polymorphism and PCa. In present meta-analysis, no
evidence has shown any associations between Ser326Cys
polymorphism and PCa susceptibility in overall
population.
The results of several studies have suggested that sin-
gle nucleotide polymorphisms may determine the differ-
ences in the risk of PCa between ethnic groups [22,23].
Ethnic differences in the incidence of PCa are well
established. So subanalysis on different ethnicity was
performed. Our data suggested that hOGG1 Ser326Cys
Table 1 Main characteristics of studies included in this meta-analysis.
Investigator [reference] Year Ethnicity Cases Controls
Ser/Ser Ser/Cys Cys/Cys Ser/Ser Ser/Cys Cys/Cys
Yun et al. [8] 2011 Asian 54 119 93 68 131 67
Zhang et al. [9] 2010 Mixed 126 61 4 118 71 7
Lavender et al. [10] 2010 African 132 58 4 452 173 21
Dhillon et al. [11] 2009 Caucasian 38 57 21 69 50 12
Nock et al. [12] 2006 Mixed 280 135 24 305 142 31
Nam et al. [13] 2005 Mixed 593 350 53 617 386 89
Chen et al. [14] 2003 Caucasian 49 29 6 185 63 3
Xu et al. [15] 2002 Caucasian 182 106 10 96 63 15
Figure 1 Forest plots for hOGG1 Ser326Cys polymorphism and risk of Prostate cancer in mixed population (Cys/Cys versus Ser/Ser).
The squares and horizontal lines correspond to the study specific OR and 95% CI. The area of the squares reflects the weight (inverse of the
variance). The diamond represents the summary OR and 95% CI.
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cant decrease in PCa risk in mixed population. However,
no significant association was detected in Caucasians.
This indicates a possible role of ethnic differences in
genetic backgrounds and the environment they lived in.
Moreover, the discrepancy might be due to chance
because studies with small sample sizes may be
underpowered to detect a slight effect or may have gen-
erated a fluctuated risk estimate. Therefore, the results
of this study should be interpreted with caution.
In the present study, statistically significant between-
study heterogeneity of genotype effect was detected
in all different genetic models when all the eligible
studies were pooled into the meta-analysis. After
Figure 2 Forest plots for hOGG1 Ser326Cys polymorphism and risk of Prostate cancer in mixed population (Cys/Cys versus Ser/Cys +
Ser/Ser). The squares and horizontal lines correspond to the study specific OR and 95% CI. The area of the squares reflects the weight (inverse
of the variance). The diamond represents the summary OR and 95% CI.
Figure 3 Forest plots for hOGG1 Ser326Cys polymorphism and risk of Prostate cancer in mixed population (Cys allele versus Ser
allele). The squares and horizontal lines correspond to the study specific OR and 95% CI. The area of the squares reflects the weight (inverse of
the variance). The diamond represents the summary OR and 95% CI.
Table 2 Meta-Analysis of hOGG1 Ser326Cys Polymorphism and PCa
Ser326Cys polymorphism Genetic
model (No. of studies)
Sample size Analysis Test of association P value for heterogeneity P value for Egger’s test
Case Control model OR (95% CI) P
Overall (8)
Cys/Cys vs Ser/Ser 1669 2155 R 1.06 (0.61-1.87) 0.83 < 0.00001 0.522
Cys/Cys vs Ser/Cys + Ser/Ser 2584 3234 R 1.00 (0.61-1.63) 0.99 < 0.0001 0.823
Cys/Cys + Ser/Cys vs Ser/Ser 2584 3234 R 1.12 (0.89-1.40) 0.33 0.001 0.082
Cys vs Ser 5168 6468 R 1.10 (0.88-1.37) 0.41 < 0.00001 0.158
Caucasian (3)
Cys/Cys vs Ser/Ser 306 292 R 1.92 (0.32-11.43) 0.47 < 0.0001 0.661
Cys/Cys vs Ser/Cys + Ser/Ser 498 556 R 1.60 (0.34-7.48) 0.55 0.0004 0.668
Cys/Cys + Ser/Cys vs Ser/Ser 498 556 R 1.50 (0.73-3.08) 0.27 0.0009 0.057
Cys vs Ser 996 1112 R 1.40 (0.70-2.78) 0.34 < 0.00001 0.251
Mixed (3)
Cys/Cys vs Ser/Ser 1080 1167 F 0.67 (0.50-0.90) 0.007 0.62 0.964
Cys/Cys vs Ser/Cys + Ser/Ser 1626 1766 F 0.68 (0.51-0.91) 0.008 0.69 0.920
Cys/Cys + Ser/Cys vs Ser/Ser 1626 1766 F 0.90 (0.78-1.03) 0.13 0.58 0.875
Cys vs Ser 3252 3532 F 0.88 (0.78-0.98) 0.02 0.54 0.982
PCa = prostate cancer; OR = odds ratio; CI = confidence interval; vs = versus; R = random effect model; F = fixed effect model.
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neity was only detected in Caucasians. The heteroge-
neity was effectively removed in mixed subgroup.
Significant between-study heterogeneity was detected
in overall and Caucasian population and we con-
ducted analyses using random effect models. Then we
got a wider confidence interval and a larger P-value
which may be distorting the meta-analysis. The data
showed that no obvious publication bias existed in
our meta-analysis.
Some limitations of this meta-analysis should be
acknowledged. First, controls were not uniformly
defined, so selection bias may occur and they may not
be representative of the general population. Second,
the number of cases and controls in the included stu-
dies was relatively low. Third, our result was based on
unadjusted estimates, while a more precise analysis
should be conducted adjusted by other factors like
smoking, drinking status and environmental factors.
Fourth, in the subgroup analyses by ethnicity, relatively
limited study number and incomplete information for
mixed ethnicities made it impossible to perform ethnic
subgroup analysis of Africans and Asians. Thus, addi-
tional studies are warranted to evaluate the effect of
this functional polymorphism on PCa risk in different
ethnicities, especially in Africans and Asians. In addi-
tion, our analysis did not consider the possibility of
gene-gene or SNP-SNP interactions or the possibility
of linkage disequilibrium between polymorphisms.
Therefore, larger and well-designed studies are needed
to further evaluate the association between hOGG1
polymorphism and PCa risk.
Conclusions
Our meta-analysis evaluated the association between
Ser326Cys polymorphism and PCa risk and revealed
that hOGG1 polymorphism Ser326Cys was associated
with a statistically significant decrease in PCa risk in
mixed population. Due to limitations showed above in
this analysis, it is critical that larger and well-designed
multicenter studies are needed to confirm our results.
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